Senti Biosciences Inc (NASDAQ: SNTI)’s stock price has plunge by -19.03relation to previous closing price of 3.66. Nevertheless, the company has seen a -25.16% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-02-25 that – Jay Cross, proven financial leader, appointed as CFO to drive strategic growth – – Faraz Siddiqui, expert in manufacturing operations, joins as SVP Technical Operations – SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced an expansion of its senior leadership team with the addition of Jay Cross as Chief Financial Officer and Faraz Siddiqui as Senior Vice President of Technical Operations.
Is It Worth Investing in Senti Biosciences Inc (NASDAQ: SNTI) Right Now?
Additionally, the 36-month beta value for SNTI is 2.49. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SNTI is 3.11M and currently, short sellers hold a 2.21% ratio of that float. The average trading volume of SNTI on February 28, 2025 was 2.43M shares.
SNTI’s Market Performance
SNTI’s stock has seen a -25.16% decrease for the week, with a -30.43% drop in the past month and a 35.94% gain in the past quarter. The volatility ratio for the week is 6.12%, and the volatility levels for the past 30 days are at 6.39% for Senti Biosciences Inc The simple moving average for the past 20 days is -26.20% for SNTI’s stock, with a -6.86% simple moving average for the past 200 days.
Analysts’ Opinion of SNTI
Many brokerage firms have already submitted their reports for SNTI stocks, with Morgan Stanley repeating the rating for SNTI by listing it as a “Equal-Weight.” The predicted price for SNTI in the upcoming period, according to Morgan Stanley is $7.50 based on the research report published on October 07, 2022 of the previous year 2022.
SNTI Trading at -28.39% from the 50-Day Moving Average
After a stumble in the market that brought SNTI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.51% of loss for the given period.
Volatility was left at 6.39%, however, over the last 30 days, the volatility rate increased by 6.12%, as shares sank -31.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -45.96% lower at present.
During the last 5 trading sessions, SNTI fell by -23.99%, which changed the moving average for the period of 200-days by -18.41% in comparison to the 20-day moving average, which settled at $4.02. In addition, Senti Biosciences Inc saw -15.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SNTI starting from Lu Timothy K, who sale 3,922 shares at the price of $4.07 back on Feb 04 ’25. After this action, Lu Timothy K now owns 82,627 shares of Senti Biosciences Inc, valued at $15,963 using the latest closing price.
Lu Timothy K, the CEO of Senti Biosciences Inc, sale 545 shares at $4.36 during a trade that took place back on Feb 06 ’25, which means that Lu Timothy K is holding 82,082 shares at $2,376 based on the most recent closing price.
Stock Fundamentals for SNTI
Current profitability levels for the company are sitting at:
- -190.09 for the present operating margin
- -12.22 for the gross margin
The net margin for Senti Biosciences Inc stands at -212.9. The total capital return value is set at -1.3. Equity return is now at value -143.27, with -74.80 for asset returns.
Based on Senti Biosciences Inc (SNTI), the company’s capital structure generated 0.68 points at debt to capital in total, while cash flow to debt ratio is standing at -1.01. The debt to equity ratio resting at 2.17. The interest coverage ratio of the stock is -56.92.
Currently, EBITDA for the company is -61.34 million with net debt to EBITDA at -0.42. When we switch over and look at the enterprise to sales, we see a ratio of 115.84. The receivables turnover for the company is 4.5for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.92.
Conclusion
In conclusion, Senti Biosciences Inc (SNTI) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
